StreetInsider.com News Articles

DexCom (DXCM) PT Raised to $95 at TD Cowen as 'CONNECT and MACE Data Impress at ADA'

Wed, 10 Jun 2026 08:30:03 -0400

TD Cowen analyst Joshua Jennings raised the price target on DexCom (NASDAQ: DXCM) to $95.00 (from $75.00) while maintaining a Buy rating.

The analyst commented: "CONNECT and MACE Data Impress at ADA; DXCM is seemingly at the forefront of the T2NIT coverage expansion initiative, and we believe CONNECT represents a compelling dataset for payers. We see DXCM as a share gainer in the US T2NIT market, but believe incremental access should benefit all players due to the size of the opportunity and efforts from DXCM/ABT to address the different needs of less-intensive patients.

DXCM shares have been moving higher since the company's

DexCom (DXCM) PT Raised to $95 at TD Cowen as 'CONNECT and MACE Data Impress at ADA'

Wed, 10 Jun 2026 08:30:03 -0400

TD Cowen analyst Joshua Jennings raised the price target on DexCom (NASDAQ: DXCM) to $95.00 (from $75.00) while maintaining a Buy rating.

DXCM shares have been moving higher since the company's

DexCom (DXCM) PT Raised to $85 at Mizuho

Tue, 09 Jun 2026 06:42:27 -0400

(Updated - June 9, 2026 6:42 AM EDT)

Mizuho analyst Anthony Petrone raised the price target on DexCom (NASDAQ: DXCM) to $85.00 (from $75.00) while maintaining a Outperform rating.

The analyst commented: "We attended the 2026 American Diabetes Association (ADA) in New Orleans where Dexcom's (DXCM-OP) randomized control trial (RCT) comparing blood sugar control in Type 2 (T2D) non-insulin patients using continuous glucose monitoring (CGM) versus routine care using blood glucose meter (BGM) monitoring. The study achieved its primary endpoint of HbA1c reduction (measure of monthly average blood sugar) with the CGM achieving an average -1.6% decline versus an average -0.7% in

DexCom (DXCM) PT Raised to $85 at Mizuho

Tue, 09 Jun 2026 06:42:27 -0400

(Updated - June 9, 2026 6:42 AM EDT)

Mizuho analyst Anthony Petrone raised the price target on DexCom (NASDAQ: DXCM) to $85.00 (from $75.00) while maintaining a Outperform rating.

Dexcom study shows glucose monitor reduces A1C in type 2 diabetes patients

Sat, 06 Jun 2026 15:18:29 -0400

DexCom Inc. (NASDAQ: DXCM) announced results from the CONNECT randomized controlled trial showing its G7 continuous glucose monitor led to a statistically significant reduction in A1C levels among people with type 2 diabetes not using insulin. The results were presented at the American Diabetes Association's Scientific Sessions in New Orleans.

The study included 283 participants across 22 primary care practices in the United States, with 265 completing the 26-week trial. Participants were randomly assigned to use either the Dexcom G7 or traditional blood glucose monitoring.

Participants using the Dexcom G7 experienced an average 1.6% A1C reduction from a baseline mean of 8.8%,

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin